Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study

Lynn Malec, An Van Damme, Anthony K. C. Chan, Mariya Spasova, Nisha Jain, Charlotte Sensinger, Jennifer Dumont, Stefan Lethagen, Manuel Carcao, Flora Peyvandi

Blood (2023) 141 (16): 1982–1989.

https://doi.org/10.1182/blood.2022017780

Published: 2023

Includes: Supplemental data

Journal Articles

Efficacy of rFVIIIFc for First-Time Immune Tolerance Induction (ITI) Therapy: Final Results from the Global, Prospective VerITI-8 Study

Lynn Malec, An Van Damme, Anthony Chan, Mariya Spasova, Nisha Jain, Charlotte Sensinger, Jennifer Dumont, Stefan Lethagen, Manuel Carcao, Flora Peyvandi

Blood (2021) 138 (Supplement 2): LBA-5.

https://doi.org/10.1182/blood-2021-155156

Published: 2021

Journal Articles

Recombinant Porcine Factor VIII in Patients with Congenital Hemophilia a with Inhibitors Undergoing Surgery: Phase 3, Multicenter, Single Arm, Open-Label Study

Christian Pfrepper, Paolo Radossi, Jerzy Windyga, Kaan Kavakli, Roger E.G. Schutgens, Nazan Sarper, Jovanna Baptista, Kayode Badejo, Bruce Ewenstein, Nisha Jain

Blood (2021) 138 (Supplement 1): 2109.

https://doi.org/10.1182/blood-2021-146179

Published: 2021

Journal Articles

Recombinant ADAMTS13 for Patients with Sickle Cell Disease: Design of a Phase 1 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study

Parth Patwari, Van Anh (Vika) Nguyen, Indranil Bhattacharya, Nisha Jain

Blood (2021) 138 (Supplement 1): 3118.

https://doi.org/10.1182/blood-2021-146150

Published: 2021

Journal Articles

Recombinant ADAMTS13 for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura: Design of a Phase 3b Open-Label Continuation Study of Prophylactic and on-Demand Treatment

Nisha Jain, Cecilia Marquez, Leah Martell

Blood (2021) 138 (Supplement 1): 4252.

https://doi.org/10.1182/blood-2021-146148

Published: 2021

Journal Articles

Patients' and Caregivers' Preferences for Different Hemophilia a Treatment Attributes

Namita Joshi, PhD MS, BPharm, Xinyi Ng, Marc Botteman, MS, MA, Nanxin Li, Rachel Shah, BS, Nisha Jain, Nicole Lyn, Jun Su

Blood (2019) 134 (Supplement_1): 2122.

https://doi.org/10.1182/blood-2019-126774

Published: 2019

Journal Articles

Cold Agglutinin Disease Transfusion Practices in the United States: An Electronic Medical Record-Based Analysis

Jun Su, Rajeshwari Punekar, Jaime Morales Arias, Nisha Jain

Blood (2019) 134 (Supplement_1): 3690.

https://doi.org/10.1182/blood-2019-122209

Published: 2019

Journal Articles

Real-World Data on the Use of rFIXFc in Subjects With Hemophilia B for Up to 3.7 Years Demonstrates Improved Bleed Control and Adherence With Reduced Treatment Burden

Amy Shapiro, Ateefa Chaudhury, Nisha Jain, Elisa Tsao, Chris Barnowski, Jing Feng, Doris Quon

Blood (2018) 132 (Supplement 1): 2493.

https://doi.org/10.1182/blood-2018-99-116909

Published: 2018

Journal Articles

Real-World Data of Immune Tolerance Induction Using rFVIIIFc in Subjects With Severe Hemophilia A With Inhibitors at High Risk for ITI Failure

Manuel Carcao, Amy Shapiro, Nina Hwang, Steven Pipe, Sanjay Ahuja, Kenneth Lieuw, MD PhD, Janice Staber, Haowei Linda Sun, Hilda Ding, Michael Wang, Macgregor Steele, Elisa Tsao, Jing Feng, Zahra Al-Khateeb, Jennifer Dumont, Nisha Jain

Blood (2018) 132 (Supplement 1): 2500.

https://doi.org/10.1182/blood-2018-99-110467

Published: 2018

Journal Articles

Changing the Paradigm in Hemophilia Care: Extended Half-Life Products (rFVIIIFc and rFIXFc)

Louis M. Aledort, MD, Nisha Jain, MBBS,MD, Nanxin Li, Sangeeta Krishnan, PharmD, Benjamin Hagberg, Jun Su, MD

Blood (2018) 132 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2018-99-114905

Published: 2018

Journal Articles

Long-Term Efficacy and Quality of Life with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia a

Michael Wang, MD, K John Pasi, Ingrid Pabinger, Prof, Bryce A. Kerlin, Roshni Kulkarni, MD, Beatrice Nolan, Raina Liesner, Simon A Brown, Hideji Hanabusa, Elisa Tsao, Bent Winding, Stefan Lethagen, Nisha Jain

Blood (2016) 128 (22): 3791.

https://doi.org/10.1182/blood.V128.22.3791.3791

Published: 2016

Journal Articles

The Immune Tolerance Induction Factor Utilizations and Costs for the Management of Male Hemophilia-a Patients Who Developed Inhibitors

Jun Su, MD, Jia Zhou, Brieana Buckley, MS, PharmD, Tom Rising, Qiang Hou, Nisha Jain

Blood (2016) 128 (22): 4758.

https://doi.org/10.1182/blood.V128.22.4758.4758

Published: 2016

NARROW

Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study

Efficacy of rFVIIIFc for First-Time Immune Tolerance Induction (ITI) Therapy: Final Results from the Global, Prospective VerITI-8 Study

Recombinant Porcine Factor VIII in Patients with Congenital Hemophilia a with Inhibitors Undergoing Surgery: Phase 3, Multicenter, Single Arm, Open-Label Study

Recombinant ADAMTS13 for Patients with Sickle Cell Disease: Design of a Phase 1 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study

Recombinant ADAMTS13 for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura: Design of a Phase 3b Open-Label Continuation Study of Prophylactic and on-Demand Treatment

Patients' and Caregivers' Preferences for Different Hemophilia a Treatment Attributes

Cold Agglutinin Disease Transfusion Practices in the United States: An Electronic Medical Record-Based Analysis

Real-World Data on the Use of rFIXFc in Subjects With Hemophilia B for Up to 3.7 Years Demonstrates Improved Bleed Control and Adherence With Reduced Treatment Burden

Real-World Data of Immune Tolerance Induction Using rFVIIIFc in Subjects With Severe Hemophilia A With Inhibitors at High Risk for ITI Failure

Changing the Paradigm in Hemophilia Care: Extended Half-Life Products (rFVIIIFc and rFIXFc)

Long-Term Efficacy and Quality of Life with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia a

The Immune Tolerance Induction Factor Utilizations and Costs for the Management of Male Hemophilia-a Patients Who Developed Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only